March 30, 2026 - 20:50

For decades, beta-blockers have been a cornerstone of treatment for adults following an uncomplicated heart attack, with many patients prescribed these medications for life. This standard practice is now facing increased scrutiny from the medical community.
Recent studies suggest that the long-term benefits of beta-blockers for patients with no history of heart failure may be less significant than previously believed. The emerging research indicates that for certain stable patients, the risks and side effects of prolonged use—which can include fatigue, dizziness, and depression—might outweigh the advantages years after the initial cardiac event.
This shifting perspective is prompting cardiologists to consider a more personalized approach to treatment. Rather than a universal, lifelong prescription, medical guidelines may increasingly move toward regular reassessment of each patient's ongoing need for the therapy. The conversation is focusing on balancing proven protective benefits in the early recovery phase with the quality of life and potential risks associated with indefinite use. This reevaluation represents a significant potential shift in post-heart attack care, emphasizing tailored treatment plans based on contemporary evidence.
May 14, 2026 - 23:22
Kate Marmion School of Public Health celebrates gift and inaugural graduating class - UT Health San AntonioThe University of Texas at San Antonio held a ceremony on Wednesday, May 13, to officially name the Kate Marmion School of Public Health. The event honored a $30 million transformational gift from...
May 14, 2026 - 11:14
Minnesota readies first-ever K-12 health education standardsAdvocates say the new standards, set to be phased in over the next three years, introduce needed guidance on nutrition, first aid, sex education, and abuse prevention. Some school watchers worry...
May 13, 2026 - 19:53
From Zambia to Harvard: How Chimba Sanga Is Fighting HIV and TB With New SkillsChimba Sanga, a physician and public health leader from Zambia, is bringing his Harvard training back home to tackle two of the country`s deadliest diseases. Sanga, currently a Master of Public...
May 13, 2026 - 01:07
AP report: Marty Makary resigning as Trump's FDA chiefMarty Makary is resigning as head of the Food and Drug Administration, according to an Associated Press report. His departure comes after a turbulent tenure marked by deep internal discord and a...